Abstract Number: 0684 • ACR Convergence 2025
Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)
Background/Purpose: Systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) significantly impacts patients’ quality of life, yet validated tools to assess this condition in Spanish-speaking populations are lacking. The…Abstract Number: PP04 • ACR Convergence 2025
MCTD and Aging – Resilience Required
Background/Purpose: I was diagnosed with MCTD at age 25. My priorities were understanding a disease I had trouble pronouncing, and trying to learn to live with…Abstract Number: 2656 • ACR Convergence 2025
Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Background/Purpose: Digital ulcers (DUs) affect approximately 50% of SSc patients, causing significant pain and disability. Current management involves both systemic and local therapies. However, the…Abstract Number: 2502 • ACR Convergence 2025
Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study
Background/Purpose: Systemic sclerosis (SSc) is a clinically and biologically heterogeneous autoimmune disease characterized by multiorgan involvement, substantial morbidity, and high mortality. Traditional classification systems (based…Abstract Number: 2493 • ACR Convergence 2025
Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
Background/Purpose: Acro-osteolysis (A-O, terminal tuft digit resorption) is characteristic of systemic sclerosis (SSc), occurring in 20-25% of patients (1). Outcome measures are much needed. Following…Abstract Number: 2483 • ACR Convergence 2025
Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Background/Purpose: Raynaud’s phenomenon (RP) is the most common manifestation of systemic sclerosis (SSc) leading to substantial pain and impaired hand function. Establishing treatment efficacy for…Abstract Number: 2471 • ACR Convergence 2025
Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use
Background/Purpose: Nailfold capillaroscopy is a key tool in the early diagnosis of systemic sclerosis and related disorders. However, incorrect image acquisition can lead to misclassification…Abstract Number: 0708 • ACR Convergence 2025
Association Of Choroidal Sub-foveal Thickness With Skin Manifestations And Serum Monocyte HDL Ratio In Patients With Systemic Sclerosis-A Case Control Study
Background/Purpose: The vascular hypothesis in systemic sclerosis (SSc) posits that vasculopathy is the initial inciting event that triggers inflammation and subsequent fibrosis in the progression…Abstract Number: 0568 • ACR Convergence 2024
Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…Abstract Number: 0700 • ACR Convergence 2024
Prospective Evaluation of Capillaroscopy in Healthy Children
Background/Purpose: Capillaroscopy is a well-established tool in the diagnosis of adult-onset rheumatic diseases and global consensus on standardisation of execution and interpretation performing capillaroscopy have…Abstract Number: 0702 • ACR Convergence 2024
AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Background/Purpose: Improved treatments for Raynaud's phenomenon in Systemic Sclerosis (SSc) are needed. A novel oral calcium channel blocker (cilnidipine), with N-type channel antagonism is being…Abstract Number: PP11 • ACR Convergence 2024
Living Well with Chronic Illness: Decades with MCTD
Background/Purpose: In the fall of 1985, I was not feeling well. I attributed my tiredness, weakness and malaise to stress and carried on. Walking upstairs I…Abstract Number: 0625 • ACR Convergence 2023
Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis
Background/Purpose: RP and its ischaemic complications are a major cause of morbidity in SSc. Non-pharmacological measures to minimise cold exposure can play a vital role…Abstract Number: 1225 • ACR Convergence 2023
Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients
Background/Purpose: Nailfold video capillaroscopy (NVC) is useful in diagnosing secondary Raynaud's phenomenon (RP) and predicting systemic sclerosis (SSc) and other CTD in adults. Recent studies…Abstract Number: 1930 • ACR Convergence 2023
Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
Background/Purpose: Blue Digit Syndrome (BDS) represents the cutaneous manifestation of numerous diseases that cause blue discoloration in one or more fingers in the absence of…
ACR Meeting Abstracts